Komo Plant-Based Foods Appoints US Sales Management Consultants

Komo Plant-Based Foods Appoints US Sales Management Consultants

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo") is pleased to announce the appointment of a U.S. sales consultant, Caboodle Consulting LLC (Caboodle), to develop Komo's retail expansion throughout the United States. Komo will work closely with the Caboodle sales management team to build out the US retail strategy. Heather Barry Whittier will be representing Komo as the Director of Sales. Ms. Whittier has 20+ years experience in the natural products industry including a pivotal role in growing a brokerage, Yin Yang Naturals, from regional to national coverage

Other members of the Caboodle management team include Lisa Thorson and Constance Wolfe. Lisa Thorson comes from a Market Analysis background with 10+ years' experience in Consumer Packaged Goods (CPG) brokerage and brand management with experience at Laird Superfood and Alliance Sales & Marketing. Constance Wolfe offers 10+ years of brand management experience including specializing in data analysis and trade spend promotional management with experience at Coconut Bliss and Hilary's Eat Well.

Caboodle is a consulting group that provides roadmaps for CPG food brands looking to expand in the U.S. grocery marketplace. Depending on their unique goals, strategies are developed utilizing customized programming including data analytics, sales management, and emerging brand fundamentals. Caboodle plans to soon launch an online platform which will serve as a digital hub for growth & management.

"The United States represents a significant opportunity for Komo," says Komo Comfort Foods President, Jeffrey Ma. "We're excited to have Heather Whittier representing Komo to build out our U.S. expansion. Her experience and contacts in the industry will be key for our U.S. strategy. We are extremely happy with the dedication of the team at Caboodle so far and look forward to the future of this relationship."

Komo has recently secured a US warehouse with HLC Distributing, based in Oregon.

About Komo

Komo Plant Based Foods Inc. is a premium plant-based food company that develops, manufactures and sells a variety of plant-based frozen meals that are always hearty, satisfying, and made with wholesome ingredients. At Komo, our mission is to help make plant-based meals a staple on every dinner table by sharing our love for feel-good food that connects the people to the planet. We believe plant-based eating is the future and - Change can start with a single biteTM. Our experienced plant-based innovation and development team recreates vegan versions of traditionally cheesy and meaty classics, with 100% plants. Komo's products are sold direct-to-consumer through our eCommerce website and a distribution network of online and brick and mortar grocery, convenience and natural retailer channels. Our operating subsidiary Komo Comfort Foods launched in 2021 with our flagship products: plant-based Lasagna, Shepherd's Pie and Chickenless Pot Pie and Komo Plant-Based Meal HelpersTM - versatile meal starters to allow the creation of many dishes at home. All of our products are 100% plant-based, made with wholesome ingredients, free from preservatives, and frozen for freshness. Komo's plant-based lasagna was award the Best New Vegan Product at the Natural Products Expo West Show in March 2022.

Learn more at: www.komocomfortfoods.com and follow on Instagram: @komocomfortfoods

For further information, please contact:

William White, President & CEO, Komo Plant Based Foods Inc.
will@komoeats.com
1-866-969-0882

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or Komo's future performance. The use of any of the words "could", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Komo's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, Komo's product development plans, its ability to launch its products on food delivery apps, its ability to retain key personnel, its revenues, and its expectation as to the acceptance of its products by retailer stores and consumers constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. Komo disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

SOURCE: KOMO Plant Based Foods Inc.



View source version on accesswire.com:
https://www.accesswire.com/702985/Komo-Plant-Based-Foods-Appoints-US-Sales-Management-Consultants

News Provided by ACCESSWIRE via QuoteMedia

YUM:CC
The Conversation (0)
Komo Expands Frozen Meal Line to Fortinos Stores in Toronto

Komo Expands Frozen Meal Line to Fortinos Stores in Toronto

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) ( the "Company", "Komo"), Komo Plant Based Foods Inc. Expands Frozen Meal Line to All 9 SKUs in Fortinos Stores in Toronto.

Komo Plant Based Foods Inc., a premium, fast-growing plant-based food products manufacturer, is thrilled to announce the expansion of their frozen meal line to all 9 SKUs in Fortinos stores across the Greater Toronto Area (GTA). The partnership will make Komo's delicious and nutritious plant-based meals more accessible to families in Toronto, helping to make healthy meal planning more convenient and affordable.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Plant Based Foods Reports Impressive Revenue Growth with a 160% Increase in Q2

Komo Plant Based Foods Reports Impressive Revenue Growth with a 160% Increase in Q2

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOD) (FSE: 9HB) ("Komo"), a premium plant-based food company, is pleased to announce it achieved record revenues for its second financial quarter ended January 31, 2023. Komo generated revenues of $466,197 in the quarter, which is a 160% increase from the first quarter revenues of $179,467. The increase is attributed to Komo's recent growth across Canada with its retail distribution through Loblaws, Loblaws banner stores, Sobeys, Whole Foods and key natural accounts. This also represents a 181% increase from last year's Q2 report which had revenue of $166,052. Komo reported a gross profit margin of 39% in Q1 of 2023.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Expands Across Canada with Whole Foods Market

Komo Expands Across Canada with Whole Foods Market

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) (the "Company", "Komo"), a premium plant‐based food company, reports planned expansion across Canada with Whole Foods Market.

Komo Plant Based Foods Inc., a fast growing plant-based food products manufacturer, announces today that it will be expanding its presence in Canada through additional distribution at Whole Foods Markets. Komo's line of frozen meals and meal helpers will now be available in all 14 Whole Foods Market locations in Canada, with the newly expanded listings to be on shelves by May of 2023.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Doubles Retail Distribution to 840 Stores

Komo Doubles Retail Distribution to 840 Stores

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) (the "Company", "Komo"), a premium plant‐based food company, reports significant growth in the number of retail stores carrying Komo products with an increase of over 100% in 3 months.

Komo Plant Based Foods Inc., a fast-growing plant-based food products manufacturer, announces a 100% increase in retail distribution since November of 2022, now available in 840 grocery retail locations across Canada. This impressive growth includes Loblaw's and Loblaws' banner stores and the addition of 50 new retail stores in January 2023, including Georgia Main Group (IGA West and Fresh St. Market), Sobey's West, Safeway and Freson Brothers locations in western Canada, and key natural accounts such as Boites à Grain in Quebec.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Komo Reports Q1 Financial Results

Komo Reports Q1 Financial Results

Komo Plant Based Foods Inc. (CSE: YUM) (OTCQB: KOMOF) (FSE: 9HB0) ( the "Company", "Komo"), a premium plant‐based food company, reports financial results for the quarterly period ended October 31, 2022.

FINANCIAL RESULTS

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sirona Biochem (TSXV:SBM)

Sirona Biochem


Keep reading...Show less
Young female researcher working in a lab.

Radiopharmaceuticals Take Investors to the Forefront of Precision Oncology

Radiopharmaceuticals are emerging as one of the most promising innovations in modern medicine, particularly in precision oncology, and if recent billion-dollar investment deals are any indication, the potential for growth can be significant. Investors eyeing exposure to this emerging technology would benefit from a deeper understanding of the technology, its strategic applications and investment opportunities.

A groundbreaking technology in the field of oncology, radiopharmaceuticals combine radioactive substances with targeted molecules to revolutionise cancer detection and treatment. These innovative compounds are gaining significant attention due to their ability to deliver precise and targeted cancer therapies, minimising damage to healthy tissues while maximising therapeutic efficacy.

At their core, radiopharmaceuticals leverage the unique properties of radioactive isotopes, pairing them with molecules that have a high affinity for cancer cells. This combination allows for both diagnostic imaging and therapeutic applications, offering a level of precision previously unattainable in traditional cancer treatments.

Keep reading...Show less

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

Howard Chang , M.D., Ph.D.,   Joins as Senior Vice President of Research and Chief Scientific Officer

Amgen (NASDAQ:AMGN) today announced that Howard Chang M.D., Ph.D., will join the company as senior vice president of Research, effective Dec. 16, 2024 . Chang will also assume the title and responsibility of serving as Amgen's chief scientific officer, reporting to Jay Bradner M.D., executive vice president of Research and Development.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Top 5 Life Science ETFs in 2024

Top 5 Life Science ETFs in 2024

Taking a position in a life science exchange-traded fund (ETF) provides exposure to a basket of stocks focused on the healthcare sector, while mitigating the risks of holding shares in a single company.

While ETFs provide diversification by their nature, fund managers often narrow down their offerings to follow a specific aspect of the market — for example, biotech or pharma. They also typically adjust the weight of ETF holdings to match movements in the life science industry in an effort to give investors the best possible returns.

There are many choices when it comes to life science ETFs, and to help investors understand their options, the Investing News Network has listed the top life science ETFs by year-on-year performance.

Keep reading...Show less
Radiopharm Theranostics

Australian Ethics Committee Approval to Expand PD-L1 Nanobody (RAD204) Phase 1 Trial in Multiple Tumor Types

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval to include participants with Programmed Death-Ligand 1 (PD-L1) positive Small Cell Lung Cancer (SCLC), Triple Negative Breast Cancer (TNBC), Melanoma, Head and Neck Cancer (HNSCC), and Endometrial Cancer, as part of its ongoing Phase 1 clinical trial of 177Lu-labelled RAD204 for the treatment of PD-L1 expressing cancers.
Keep reading...Show less
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Marked and rapid reductions in both pericarditis pain and inflammation
maintained throughout the 26-week study

Episodes of pericarditis per year substantially reduced

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×